SOURCE: Velcera, Inc.

September 17, 2007 06:00 ET

Velcera to Present at Maxim Group Growth Conference

YARDLEY, PA--(Marketwire - September 17, 2007) - Velcera, Inc., a specialty pharmaceutical company focused on pet health, announced today that the company will be presenting at the Maxim Group Growth Conference September 20, 2007 at the Grand Hyatt Hotel in New York City. The company's chief executive officer, Dennis Steadman, is scheduled to present on Thursday, September 20 at 8:00 a.m. (EDT).

To access a live audio webcast of Mr. Steadman's presentation, please log onto Velcera's website at http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=W215153&item_id approximately 15 minutes prior to the presentation in order to register and download any necessary software. Shortly after the presentation, the webcast will be available on Velcera's website at www.velcera.com and archived for 90 days.

The Maxim Group Growth Conference will feature interactive presentations from over 70 companies, as well as one-on-one meetings with executives from the Healthcare, Technology, and Special Situations Sectors. For more information on this event please visit http://www.maximgrp.com/growthconf/.

About Velcera, Inc.

Velcera is a specialty pharmaceutical company focused on leveraging its patented PROMIST™ delivery system to develop veterinary medicines with superior convenience, compliance, and pharmacokinetic advantages that benefit pets and their owners. The PROMIST delivery system provides a metered dose liquid mist to the oral mucosa for systemic absorption. The convenience of PROMIST has the potential to increase compliance and improve pet health as owners avoid the challenge involved in getting their pets to swallow pills. Other advantages of PROMIST include improved bioavailability, faster absorption and avoidance of the GI tract.

As a patented technology, PROMIST attracts strategic partners by extending the patent life of medication based on the delivery system. Current collaborations include a global licensing agreement with Novartis Animal Health covering Velcera's first product, a novel canine product utilizing Velcera's patented PROMIST technology, as well as formulation and manufacturing agreements with The Chao Center at the University of Purdue and Argenta Manufacturing Ltd. To date, PROMIST has shown significantly improved bioavailabilty, speed of drug absorption, and ease of administration when evaluated in dogs, cats and horses.

Contact Information

  • For more information, please contact:

    Velcera, Inc.
    Dennis Steadman
    President and CEO
    Phone: 267-757-3600
    Email Contact

    The Ruth Group
    Sara Ephraim (investors)
    Phone: 646-536-7002
    Email Contact

    Jason Rando (media)
    Phone: 646-536-7025
    Email Contact